medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2014; 13 (4)


Persistent hepatic encephalopathy secondary to portosystemic shunt occluded with Amplatzer device

Ramírez-Polo A, Márquez-Guillén E, González-Aguirre AJ, Casanova-Sánchez IE, Chávez-Ruiz R, Carrillo-Maravilla E, López-Méndez E

Idioma: Ingles.
Referencias bibliográficas: 28
Paginas: 456-460
Archivo PDF: 251.31 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Degos B, Daelman L, Huberfeld G, Meppiel E, Rabier D, Galanaud D, Magis AS, et al. Portosystemic shunts: An underdiagnosed but treatable cause of neurological and psychiatric disorders. J Neurol Sciences 2012; 32: 58-64.

  2. Tashiro H, Ide K, Amano H, Kobayashi T, Onoe T, Ishiyama K, Kuroda S, et al. Surgical treatment for portosystemic encephalopathy in patients with liver cirrhosis: Occlusion of portosystemic shunt in combination with splenectomy. Hepatol Res 2012; DOI: 10.1111.

  3. Mukund A, Rajesh S, Arora A, Patidar Y, Jain D, Sarin SK. Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience. J Vasc Interv Radiol 2012; 23: 1200-6.

  4. Rahimi RS, Rockey DC. Complications of cirrhosis. Curr Opin Gastroenterol 2012; 28: 223-9.

  5. Khungar V, Poordad F. Hepatic Encephalopathy. Clin Liver Dis 2012; 16: 301-20.

  6. Córdoba J. New assessment of hepatic encephalopathy. J Hepatol 2011; 54: 1030-40.

  7. Córdoba J, Mínguez B. Hepatic Encephalopathy. Semin Liver Dis 2008; 28: 70-80.

  8. Macías-Rodríguez RU, Torre A. Diagnostic approach to persistent hepatic encephalopathy. Rev Gastroenterol Mex 2011; 76: 345-52.

  9. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515-25.

  10. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Eng J Med 1997; 337: 473-9.

  11. Poh Z, Chang PEJ. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Inter J Hepatology 2012; 480309.

  12. Romero-Gómez M. Pharmacotherapy of hepatic encephalopathy in cirrhosis. Expert Opin Pharmacother 2010; 11: 1317-27.

  13. Wakim-Fleming J. Hepatic encephalopathy: suspect it early in patients with cirrhosis. Cleve Clin J Med 2011; 78: 597-605.

  14. Eroglu Y, Byrne WJ. Hepatic encephalopathy. Emerg Med Clin N Am 2009; 27: 401-14.

  15. Bajaj JS. The modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 537-47.

  16. Als-Nielsen B, Gluud LL, Gluud C. Non absorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev 2004; 2: CD003044.

  17. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046.

  18. van Leeuwen PA, van Berlo CL, Soeters PB. New mode of action for lactulose. Lancet 1988; 1: 55-6.

  19. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, et al. Rifaximin Treatment in Hepatic Encephalopathy. N Engl J Med 2010; 362: 1071-81.

  20. Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, et al; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, doubleblind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 51-8.

  21. Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 2012; 18: 767-77.

  22. Jiang Q, Jiang XH, Zheng MH, Chen YP. L-Ornithine-L-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 2009; 24: 9-14.

  23. Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther 2012; 92: 321-31.

  24. Sicklick JK, D’Angelica. Fong Y. The liver. In: Townsend CM (ed) Sabiston Textbook of Surgery, The Biological Basis of Modern Surgical Practice. 19th. Ed. Philadelphia: Saunders- Elselvier; 2012, p. 1431.

  25. Alonso-Gamarra E, Parrón M, Pérez A, Prieto C, Hierro L, López-Santamaría M. Clinical and radiologic manifestations of congenital extrahepatic portosystemic shunts: a comprehensive review. Radiographics 2011; 31: 707-22.

  26. Kobayashi N, Niwa T, Kirikoshi H, Fujita K, Yoneda M, Saito S, Nakajima A. Clinical classification of congenital extrahepatic portosystemic shunts. Hepatol Res 2010; 40: 585-93.

  27. Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 1996; 11: 51-8.

  28. Boixadera H, Tomasello A, Quiroga S, Cordoba J, Perez M, Segarra A. Successful embolization of a spontaneous mesocaval shunt using the Amplatzer Vascular Plug II. Cardiovasc Intervent Radiol 2010; 33: 1044-8.




2020     |     www.medigraphic.com